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Abstract: Multiple Sclerosis (MS) is an inflammatory demyelinating neurodegenerative 
disorder of the brain and spinal cord that causes significant disability in young adults. 
Although the precise aetiopathogenesis of MS remains unresolved, its pathological 
hallmarks include inflammation, demyelination, axonal injury (acute and chronic), 
astrogliosis and variable remyelination. Despite major recent advances in therapeutics for 
the early stage of the disease there are currently no disease modifying treatments for the 
progressive stage of disease, whose pathological substrate is axonal degeneration. This 
represents the great and unmet clinical need in MS. Against this background, human stem 
cells offer promise both to improve understanding of disease mechanism(s) through  
in-vitro modeling as well as potentially direct use to supplement and promote 
remyelination, an endogenous reparative process where entire myelin sheaths are restored 
to demyelinated axons. Conceptually, stem cells can act directly to myelinate axons or 
indirectly through different mechanisms to promote endogenous repair; importantly these 
two mechanisms of action are not mutually exclusive. We propose that discovery of novel 
methods to invoke or enhance remyelination in MS may be the most effective therapeutic 
strategy to limit axonal damage and instigate restoration of structure and function in this 
debilitating condition. Human stem cell derived neurons and glia, including patient specific 
cells derived through reprogramming, provide an unprecedented experimental system to 
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model MS “in a dish” as well as enable high-throughput drug discovery. Finally, we 
speculate upon the potential role for stem cell based therapies in MS. 
Keywords: multiple sclerosis (MS); embryonic stem cells (ESCs); pluripotent stem cells 
(PSCs); induced pluripotent stem cells (iPSCs); neurodegenerative disease 
 
1. Introduction 
Multiple Sclerosis (MS) is a chronic inflammatory and progressive demyelinating disorder of the 
central nervous system that causes significant morbidity. It has a prevalence of 1.2 per 1000 and a 
lifetime risk of 1 in 400 [1]. Although an interplay of genetic and environmental factors are likely to be 
contributory, the precise aetiopathogenesis of MS remains unresolved. Its pathological hallmarks 
include multi-focal inflammation, primary demyelination (where axons pathologically lose their 
investing myelin sheaths), acute and chronic axonal damage and astrogliosis. The majority of patients 
experience two disease phases; relapsing-remitting (RR) followed by a secondary progressive (SP) 
course. The former is pathologically characterised by inflammatory activity while SPMS is dominated 
by neurodegeneration and variable remyelination. Major recent advances in anti-inflammatory disease 
modifying treatments (DMTs) have transformed the outlook of newly diagnosed RRMS patients. 
However, whether these DMTs will influence the later progressive stage that accounts for 
accumulating disability is unknown. In addition approximately 15% of patients experience a 
progressive course from diagnosis that again is not responsive to currently available DMTs. The unmet 
need is therefore for novel neuroprotective therapeutics.  
2. Repair in MS 
MS is the prototypic immune-mediated demyelinating disease characterized pathologically by  
mult-focal and multi-phasic inflammatory demyelinating lesions of the central neuraxis. Blood-brain 
barrier breakdown and subsequent (multi-) focal inflammation typically leads to clinical  
disability in the form of discrete relapses. In addition to targeting a particular neural cell type 
(oligodendrocytes-responsible for myelination in the central neuraxis), MS additionally exhibits 
regional bias with particular sites of predilection, including the optic nerves, periventricular white 
matter, cerebellum and corpus callosum. Most MS patients develop progressive and permanent 
neurological deficit after 10–15 years of disease activity. Axonal loss and progressive brain atrophy 
are histologically and radiologically conspicuous features of MS [2–6], and comprise the pathological 
substrate for accumulating neurological disability. Studies exploring axonal pathology/loss have reported 
its occurrence in both acute and chronic MS plaques and even in normal appearing white matter [2–4,7]. 
Precise underlying mechanisms remain unresolved but these aforementioned studies and others argue 
for both inflammation-related [8] and inflammation-independent mechanisms of axonal loss. 
The major therapeutic goal in MS is neuroprotection; two important components of this goal are the 
promotion of remyelination [9] and the prevention of axonal loss [10]. In vivo studies demonstrate that 
these two processes are intricately coupled, and suggest that remyelination will serve to protect  
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axons [11–13] in addition to restoring saltatory conduction. To this end, the human central nervous 
system does possess some capacity for variable degrees of remyelination, which can even be extensive 
in some cases [14,15]. Although remyelination results in thinner and shorter myelin sheath 
“internodes” than would be expected for a given diameter of axon [16,17], its potential as a  
reparative strategy is clearly demonstrated by experimental association with resolution of function 
deficits in animal models [18,19]. Unfortunately, however, remyelination ultimately fails to keep  
pace with disease progression and neurological deficit accumulates. Understanding why endogenous 
remeylination appears to fail in some patients and is variable across different lesions in the same 
individual is critical to guiding therapeutic strategy.  
Following an episode of demyelination, sodium channels (usually concentrated at the nodes of 
Ranvier) redistribute as a compensatory mechanism thus allowing conduction to be maintained [20,21] 
(and conduction block avoided). The resulting action potentials are, however, delayed and continuous 
rather than fast and saltatory. In addition to ensheathing/myelinating axons, oligodendrocytes also 
contribute to axonal stability, axonal length and neurofilament regulation, sodium channel clustering 
and neuronal survival [22–30]. The observation that specific genetic defects affecting myelin lead to 
axonal degeneration in mice [31,32] reinforces the notion that axonal survival ultimately requires 
oligodendrocyte-mediated trophic support. Indeed in MS post-mortem tissue, axon preservation is seen 
in remyelinated lesions; again reinforcing the concept of a supportive role for myelin in axon 
protection [12]. Such studies raise the hypothesis that there are oligodendroglia-derived factors that 
protect axons; indeed insulin like growth factor 1 (IgF1) and glial derived neurotrophic factor (GDNF) 
have been shown to be produced by oligodendrocytes in cell culture where they do exert  
axon-protective effects [29,30]. The mechanistic advantages for promoting remyelination are thus not 
only to restore saltatory conduction; but also to protect the axon from “bystander” inflammatory 
damage (a concept supported by considerable albeit indirect experimental evidence) [12,32,33]. 
Cell-based remyelination is the focus of many experimental studies. This can theoretically be 
accomplished by exogenous promotion of endogenous remyelination or more directly by exogenous 
myelinogenic cells, although it is important to appreciate that these two mechanisms are not mutually 
exclusive. Despite classic dogma from early neuroanatomists like Cajal, the adult mammalian CNS 
does indeed contain populations of resident, proliferating and multipotent neural stem cells [34]. These 
adult stem cells are concentrated in the subventricular zone and hippocampus, and are also diffusely 
distributed throughout the neuraxis in the form oligodendrocyte precursor cells (OPCs) [35,36]. The 
OPC may well have the potential to behave as a neural stem cell in the context of injury, representing  
a new approach to brain repair. An increasing body of evidence suggests that remyelinating 
oligodendrocytes arise from adult OPCs [37–42]. Whether this represents a completely homogenous 
precursor population within the adult neuraxis has yet to be resolved; region specific molecular and 
functional diversity within the OPC population is certainly possible and will greatly inform future 
efforts to generate such cells for modeling disease mechanisms and for their potential use as a 
therapeutic strategy.  
Why remyelination fails in some lesions but not others is unknown [43]. Some of the putative 
mechanisms for remyelination failure are depicted in Figure 1. Clearly the preservation of axonal 
integrity within a lesion is a key determinant of successful remyelination (i.e., there must be viable 
“targets” to remyelinate). The repopulation of demyelinated areas by adult OPCs is robust [44], 
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suggesting that repeated bouts of demyelination/remyelination to individual foci should not 
subsequently deplete OPC reserve and cause remyelination failure [45]. It has been argued, however, 
that if there is insufficient “recovery” time between episodes of inflammatory demyelination  
(i.e., repeated / continuous disease activity), this may well contribute to remyelination failure [46,47]. 
A failure of OPC recruitment has also been raised as a possible mechanism of remyelination  
failure [48] and is supported by the finding of patients who generate antibodies to OPC-expressed 
antigens [49] or aberrant expression of local guidance cues [50]. Differentiation block of  
intralesional premyelinating oligodendrocytes has also been implicated as a contributor to 
remyelination failure [51–54]. The presence of myelin debris containing myelin associated 
differentiation inhibitory proteins also reduces the efficiency of remyelination [55]; age related  
decline in the macrophage response may be relevant here [56,57]. Changes in molecular expression on 
demyelinating axons have again been implicated in remyelination failure [58,59], as has intralesional 
astroglial phenotype [60–62]. Additional factors influencing the efficiency of experimental 
remyelination include age [57], sex [63] and genetic background [64].  
Figure 1. Putative mechanisms of remyelination failure. 
 
Pathological studies from patients with early and aggressive multiple sclerosis have proven to be a 
valuable resource for understanding early pathological events [65,66], including those associated  
with remyelination failure. Neuropathological studies of such (hyper-) acute lesions exhibiting 
remyelination failure have been associated with the following phenomena: presence of differentiated 
oligodendrocytes, astrocyte/oligodendrocyte interaction (emperipolesis), malformed (nodular) myelin 
sheaths, active demyelination of remyelinated lesions (“second hit” lesions). Importantly, the pattern 
of active demyelination appears to be the same in all newly forming lesions. Remyelination failure 
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appears to begin early in the course of MS, and occurs following the reappearance of differentiated 
oligodendrocytes in recently demyelinated tissue (Patani, Barnett and Prineas, unpublished 
observations). These findings reinforce the importance of early intervention to overcome remyelination 
failure, but also highlight the need to understand the mechanisms underpinning this phenomenon [48].  
Detailed pathological analyses of more chronic progressive MS cases have also yielded valuable 
insights including an association of progressive disease with insoluble tau accumulation [67,68], not 
seen in early aggressive disease [66]. Further similar studies are necessary not only to refine current 
lesion taxonomy, but also to deepen our understanding of the cellular and molecular temporal 
evolution of demyelinating lesions. Additionally, it is critical to better understand the precise 
mechanisms of endogenous repair and how these might be optimally invoked during the early phase of 
disease. Indeed, the molecular basis of remyelination is now beginning to be elucidated; by using 
stage-specific comprehensive transcriptional profiling of spontaneous remyelination in a rodent model, 
a recent study found that retinoid acid receptor RXR-γ transcripts were differentially expressed in cells 
of the oligodendrocyte lineage. The study, using a variety of methods, went on to show that RXR-γ is a 
positive regulator of endogenous oligodendrocyte precursor cell differentiation and remyelination [69], 
raising the prospect of retinoid pathway manipulation as a pharmacological target for regenerative 
therapy in MS. 
3. Experimental Models to Understand Disease Mechanisms and Evaluate  
Therapeutic Approaches 
Classical and indispensible experimental systems employing in vivo (transgenic or lesion-based 
models; Table 1) and cell line studies are unable to comprehensively recapitulate the complexity and 
precise biology of the human system. Despite considerable evolutionary conservation between 
vertebrates there are important differences that need to be addressed in order to improve the 
translational yield of experimental studies. In addition to accumulating evidence for developmental, 
anatomical and functional evolutionary divergence between rodents and primates [70–73], intricate 
cellular processes including neuroprotective pathways have also been shown to differ [74,75],  
and these findings further reinforce the importance of complementary human experimental  
approaches [76]. An important major interspecies difference is the proportion of glia within the 
nervous system, which is far higher in humans; a fact that is of particular interest in the current review. 
Table 1. Some of the current animal models of MS. 
Animal model Phenotype Main utility/comments 
Myelin mutant  
e.g.,  
(1) Shiverer (myelin basic protein, MBP)  
(2) Rumpshaker (proteolipid protein, PLP) 
(3) Jimpy (proteolipid protein, PLP)  
(4) Myelin associated glycoprotein (MAG) 
knockouts 
Dysmyelination  
Altered neurotransmission  
In some cases “clinical” 
disease 
To study myelination and/or 
related axonopathy 
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Table 1. Cont. 
Animal model Phenotype Main utility/comments 
Toxin based  
e.g.,  
(1) Cuprizone  
(2) Ethidium bromide  
(3) Lysolecithin  
(4) MAG-knockouts 
Focal toxic 
demyelination 
To study demyelination and 
remyelination 
Viral models  
e.g.,  
(1) Semliki Forest Virus  
(2) Theiler’s Murine Encephalomyelitis Virus 
(3) Canine distemper  
(4) Visna infection of sheep  
(5) Infection of non-human primates 
Viral/autoimmune 
demyelinating disease 
To study demyelination and 
remyelination 
Autoimmune models  
e.g.,  
(1) Experimental allergic encephalomyelitis 
(EAE); many subtypes, including active and 
adoptive-transfer in mice or rats. 
Autoimmune 
demyelination 
Monophasic or  
relapsing-remitting. 
This represents the main model 
system used. Major differences 
exist between EAE and MS; EAE 
requires active sensitization with 
brain antigens where as MS is a 
spontaneous disease. 
Spontaneous models of EAE 
have been developed but these 
necessitate transgenic approaches 
+/− strong immune adjuvants. 
Additionally, therapeutic strategies initially shown to be efficacious in animal disease models have 
proved unsuccessful in several cases when translated to pre-clinical and clinical human trials [77–80]. 
Therefore, human systems are required to complement existing experimental models in discovering 
disease mechanisms and therapeutic targets of direct relevance to human disease. Such model systems 
are accessible to some extent through human diagnostic tissue biopsy samples and post-mortem 
specimens. However, limited tissue availability, cellular viability, effects of post-mortem delay, and 
crucially the difficulty of obtaining material that accurately recapitulates early stages of the disease 
process [81], are major limitations of this strategy.  
Against this background, the isolation of human embryonic stem cells (hESCs) [82] and subsequent 
directed differentiation to regionally defined neurons [83–89] and glia [90–95] coupled with recent 
developments in nuclear reprogramming [96–98] have generated unprecedented experimental 
opportunities around using human stem cells to both better understand mechanisms underlying 
neurological diseases such as MS, and for use in their treatment. More specifically, it is now possible 
to create reductionist in vitro myelination co-culture systems to precisely elucidate mechanisms  
of demyelination, axonal injury and remyelination. Application of various injury paradigms  
(e.g., nutritional deprivation, oxidate stress) to these co-culture models can be utilized to gain further 
insight into the molecular pathogenesis of MS as previously described [28–30,99]. Such human  
in vitro myelination co-culture systems will facilitate the discovery of novel therapeutics in a more 
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focused and clinically relevant manner. Such approaches will complement existing and indispensible 
in-vivo model systems. 
4. Stem Cells 
A stem cell is defined as having the ability to both self-renew and generate specialised cell types. 
The differentiation of a stem cell to a specialized cell type is often simplified to a series of 
phenotypically defined populations, but in fact this is a continuum with multiple specific genetic steps 
(which may overlap). Human stem cells are of value as both an experimental resource (to study disease 
mechanisms and for drug discovery) and, potentially, a therapeutic strategy. Their ability to generate 
almost unlimited numbers of potentially clinical grade region-specific functional neuronal and glial 
populations while remaining karyotypically stable makes them a valuable resource.  
A common taxonomy of stem cells is based on the developmental stage of isolation, which in turn 
determines the repertoire of specialised cell types they can generate (or their “potency”). Stem cells 
isolated from early stages of development possess greater potency than those from later in 
development. Embryonic stem cells (ESCs) are a type of pluripotent stem cell (PSC) that posses the 
greatest potency in vitro, responding predictably to developmental cues. Human ESCs (hESCs) were 
first isolated by Jamie Thompson’s laboratory in 1998 [82] from the inner cell mass of the blastocyst 
from where cells were subsequently grown in culture using established methods [100–102]. The 
introduction of chemically defined hESC culture and differentiation has strengthened the prospect of 
establishing clinical-grade cells for use in regenerative medicine [103,104].  
Initial attempts to derive pluripotent stem cells by different methods were largely inspired by early 
nuclear transfer experiments from Sirs John Gurdon and Ian Wilmut [105,106]. These efforts focussed 
on nuclear reprogramming by somatic cell nuclear transfer (SCNT) and cell fusion techniques [107]. A 
more recent method of generating patient-specific PSCs is based on the discovery that somatic cell 
nuclei e.g., Fibroblasts can be directly reprogrammed to an embryonic stem cell-like pluripotent state 
without the need for eggs through introduction of a quartet of transcription factors. These can be 
introduced into somatic fibroblasts using standard methodology available in many labs [98]. These 
cells are referred to as induced pluripotent stem cells (iPSCs). Importantly, this approach has also been 
demonstrated using human somatic cells [97]. Induction of the pluripotent state originally necessitated 
transduction (viral transfection) of four transcription factors, including the oncogenic c-myc 
transcription factor. However, progress has since been made to improve efficiency and/or reduce the 
need for genetic manipulations [108–110]. Human iPSCs thus offer a unique opportunity to derive 
patient specific cell lines to model neurological diseases such as MS. These recent and transformative 
developments in reprogramming biology have demonstrated the practical feasibility of deriving patient 
specific functional cell types from readily accessible patient somatic cells, either directly by forward 
programming, trans-differentiation or via an induced pluripotent state [97,98,111,112].  
Human ESCs and iPSCs thus represent a powerful and unparalleled experimental opportunity to 
model neurodegenerative disease by virtue of their competence to respond to developmental signals 
permitting specification of functional neurons and glia. Thus far, directed differentiation has been 
achieved to various region-specific fates including human spinal cord, midbrain and forebrain  
neurons [83–85,87,113,114]. These studies support the faithful recapitulation of spatio-temporally 
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regulated developmental responsiveness to appropriate extrinsic morphogenetic signals permitting 
systematic manipulation of cell fate. Although this represents a significant advance, the next challenge 
is understanding how highly refined sub-region specific neuronal and glial diversity is generated. 
Recent studies suggest that in vitro human stem cell based systems can begin to capture this  
diversity [89,90]. Establishing how faithfully such differentiated cell populations resemble their 
somatic counterparts (foetal and adult) is also critical in understanding their true utility to accurately 
model disease [115].  
Human iPSCs offer an advantage over hESCs in enabling study of patient specific lines including 
disease-causing mutations from routine manipulation of readily available patient material [81,116]. 
The promise of stem cells as tools for understanding the mechanisms of neurological disease has been 
realized more so than their promise for neurological repair. To date, proof-of-concept studies using 
iPSCs have recapitulated the pathological phenotype of neurons from patients with inherited and 
sporadic developmental and adult brain disorders that include spinal muscular atrophy [117], familial 
dyautonomia [118], Rett syndrome [119], Parkinson’s disease [120] and Motor neuron disease [121]; 
and have provided novel insights into disease mechanisms and potential therapeutic targets.  
Compared to ESCs, stem cells isolated at later developmental stages (e.g., foetal stem cells) possess 
restricted phenotypic potentials that are defined by both the tissue and the tissue sub-region  
from which they are isolated. Several studies have demonstrated that these cells cannot be readily 
directed towards a myelinating cell fate, a desirable attribute in demyelinating conditions such as  
MS [122–125]. Given the numbers of cells required for experimental or therapeutic application, 
regional restriction represents a potential problem because this cannot, at present, be predictably 
manipulated using extrinsic signals.  
5. Human Pluripotent Stem Cells (hPSCs) as a Disease Model System for MS 
The concept of cell autonomous vs. non-cell autonomous mechanisms of disease is of considerable 
importance in this context, and can be directly addressed using a hPSC-based model system. One 
major challenge of using such an approach for the study of MS disease mechanisms is the difficulty of 
reliably generating oligodendrocytes from hPSCs [73], although this has been achieved—using 
different methods—by several groups [92,93,95]. Indeed, studies have already highlighted 
evolutionarily divergent signaling pathways in deriving oligodendrocytes from human compared to 
mouse ESCs, from which oligodendrogenesis and subsequent expansion of precursor populations is 
more easily achieved [95]. Given the likely interplay between genetic factors and environmental 
influences in MS, deriving iPSCs from this patient group may well be of value. Reductionist 
experimental paradigms may include generating oligodendrocytes from iPSCs derived from an MS 
patient and modulating the in vitro environment to model injury and repair in MS. Oligodendrocytes 
can then be used to myelinate neurons derived from the same hPSCs. Such myelination co-cultures can 
then be perturbed using injurious stimuli known to be relevant in MS in order to elucidate the precise 
mechanisms disrupting integrity of the neuron–oligodendrocyte interaction. Systematically and 
incrementally increasing the complexity of such co-culture systems will ultimately allow precise 
recapitulation and understanding of the key pathological phenomena in MS.  
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Similar studies using rodent systems demonstrate the practical feasibility and conceptual value of 
such approaches; they have elegantly identified some of the mechanisms by which oligodendrocytes 
are neuroprotective [29,30], including in the context of nitric oxide mediated neuronal and axonal 
injury [28]. Others have utilized different co-culture paradigms using activated CNS microglia and 
neurons and explored the mechanisms of injury and neuroprotection in this context [99]. “Genome 
editing” of the disease-specific iPSC line by the use of zinc finger nuclease mediated tailored genome 
engineering could be used to establish the influence of gene candidates identified from previous 
genetic studies [8,31,32] on iPSC-derived oligodendrocyte vulnerability [126–130]. Such approaches 
have significant potential to unravel the complexities of temporal dynamics and aberrant molecular 
events in different phases of MS lesion evolution. Furthermore, they raise the prospect for drug 
discovery by high throughput in vitro screening. 
The dynamic and evolving role of astrocytes in neurodegeneration and neuroprotection is  
another particularly relevant example of cell autonomous vs. non-cell autonomous mechanisms  
of disease. The recent paradigm shift in motor neuron disease being (at least in part) an  
astrogliopathy [131–133] highlights the importance of cellular autonomy studies. It is also possible to 
explore the role of cell autonomous vs. non-cell autonomous mechanisms of oligodendrocyte injury 
and protection using similar strategies in co-culture paradigms (e.g., myelinated neurons with mutant 
vs. healthy astrocytes). The emerging neuroprotective role of astrocytes is also both of great interest 
and potential relevance neurodegenerative disease [134], although this has yet to be systematically 
explored in the context of MS. Further sophistication of experimental design could be to explore the 
vulnerability of region-specific oligodendrocytes or isotopic (similar/same regional identities) vs. 
anisotopic (different regional identities) co-culture paradigms. There is some evidence from using 
isotopic (midbrain) foetal astrocytes in co-culture with ESC derived midbrain dopaminergic neurons, 
which suggests that such experiments will be informative [135]. 
6. Stem Cell Therapy in MS 
Broadly, stem cell therapy could work by two mechanisms, which are not mutually exclusive:  
(i) exogenous cell replacement and (ii) by enhancing endogenous repair.  
6.1. Exogenous Cellular Repair 
Once the desired cell type (OPC) has generated it must be rigorously characterized to qualify as a 
viable therapeutic candidate. The cells must have the robustness to survive and migrate through the 
pathological host milieu in order to myelinate denuded axons, exist is sufficient numbers, retain to 
capacity to proliferate and avoid immune rejection, while not causing tumor formation. Successful 
remyelination has been achieved experimentally in a range of animal models and using a variety  
of cell types. These have included embryonic- and adult-derived cells of the oligodendrocyte  
lineage, Schwann cells, olfactory ensheathing cells (OECs), and neural precursors (NPCs) and  
non-NPCs [41,136–144]. OECs and Schwann cells are the only potentially autologous adult human 
cell populations with myelinating potential. OECs promote and augment axon growth [145] and may 
also have a role in myelin repair [136,139,146,147]. Olfactory ensheathing cells appear to be able to 
migrate through and more readily integrate into an astrocytic environment [148,149], which is clearly 
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advantageous in MS given the pathological hallmark of astroglial scar formation. Schwann cell possess 
the theoretical advantage of being antigenically distinct, thus resistant to ongoing injury in MS,  
to oligodendrocytes.  
However, the translatability of these findings in acute monophasic rodent models to human MS, 
which is a relapsing-remitting chronic inflammatory condition, is less clear. Recognition of different 
lesion pathological phenotypes [150] also raises the question of whether different bespoke reparative 
strategies may be necessary. Furthermore, different disease courses (and indeed distinct phases within 
one disease course) may necessitate different therapeutic considerations [151]. Additionally, there is 
evidence that immune cells have diverse roles in the context of lesion evolution; there is evidence that 
macrophage depletion inhibits remyelination in experimental models [56] and in human post mortem 
studies, macrophage density at lesion borders has been positively correlated with remyelination [15]. 
These and other insights from experimental studies and post-mortem human pathological analyses 
indicate that more acute lesions represent optimal targets for transplantation-mediated repair, given the 
relative preservation of axons as targets for remyelination [15,55,56,152,153]. They also bring into 
question current clinical approaches to managing relapses (do high doses of steroids—which will 
effectively “deplete” macrophages in addition to other arms of the immune system—have a deleterious 
effect on endogenous reparative mechanisms?). Clearly the temporal dynamics of depletion and 
repopulation together with the optimal timing of remyelination and interplay between macrophages 
and other cell types, are important considerations to comprehensively address this particular question. 
Multiple specific genetic steps contribute to the transition from stem cell to a terminally 
differentiated state, raising the question of which specific point in the differentiation process provides 
cells best suited to the desired therapeutic goal. Successful therapeutic strategies require consideration 
of both (i) the pathogenic environment into which cells are to be deployed, and (ii) the desired 
therapeutic action (e.g., immunomodulation, stimulation of endogenous repair systems, or cell 
replacement). For example, an inflammatory environment has been shown to promote astrocyte 
specification from NPCs [154], whereas transplantation of OPCs into this environment results in 
functional remyelination [153]. Assuming a therapeutic objective of exogenous remyelination, the 
precise stage of ex vivo lineage commitment is of critical importance. This is illustrated  
by the demonstration in animal models (attempting to achieve exogenous remyelination)  
that mature oligodendrocytes are ineffective whereas oligodendrocyte progenitor cells (OPCs),  
(e.g., hESC-derived) succeed and remyelinate [93]. These issues highlight several important concepts 
in cellular repair strategies that may affect the therapeutic potential of the cell type in question, 
including through altering post-transplantation cell fate. Further understanding of the interplay 
between pre-implantation differentiation state (i.e., the degree of lineage commitment) and the effects 
of host environment on post-implantation lineage subspecification are thus critical if the promise of 
stem cells is to be realised in the clinical arena.  
6.2. Promotion of Endogenous Repair Mechanisms 
Of these two strategies, promoting endogenous repair may prove more clinically realistic and 
practically feasible in the near future. Specifically, given that repopulation of MS plaques with 
functional OPCs is robust, the virtue of transplanting OPCs into such lesions is questionable and may 
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be unnecessary. As endogenous remyelination can be extensive [14,15] and resident OPCs robustly 
repopulate demyelinated lesions, an ideal approach to enhancing remyelination is to target endogenous 
repair. A pre-requisite to this approach, however, is elucidating the molecular mechanisms of 
remyelination and its ultimate failure in order to identify therapeutic targets.  
In MS lesions, rather than addition of more OPCs, it is the inhibitory lesion environment that needs 
to be manipulated into one that is more permissive for remyelination. Ex vivo pre-transplantation 
manipulation of stem cells is a possible strategy here; but it seems more intuitive to engage the 
abundant endogenous OPC population (possibly through exogenous stem cells). Against that 
background, a further noteworthy generic attribute of stem cells is the capacity to dynamically interact 
with the microenvironment they migrate to in a manner that may be beneficial to the host, or 
“therapeutic plasticity”. Promoting endogenous repair might also be achieved by transplanting 
engineered stem cells that secrete growth factors (e.g., platelet derived growth factor [155]) or targeted 
drug delivery (e.g., fibroblast growth factor pathway antagonist [156]) that exploits the innate 
attraction of stem cells to areas of pathology (a generic property called “pathotropism”).  
Stem cells can also be isolated from non-neural tissues throughout life (e.g., mesenchymal stem 
cells isolated from bone marrow). Although these cell populations do not reliably generate functional 
neural derivatives, their therapeutic potential arises from their biological properties through either the 
direct constitutive actions of the cells in question, such as immunomodulatory, or through their use as a 
vehicle following ex-vivo manipulation to secrete growth factors as mentioned above. A recent clinical 
trial has confirmed that autologous MSCs can be safely administered intravenously in secondary 
progressive MS with some evidence to suggest structural, functional and physiological improvement 
following treatment consistent with neuroprotection [157]. It is likely that any improvement in this 
context was achieved through different indirect mechanisms (e.g., immunomodulation), harnessing 
endogenous repair. Clearly such studies need to be repeated with larger numbers of patients, but do 
already provide reason for cautious optimism.  
7. Concluding Remarks 
Current therapeutic strategies for MS focus on symptomatic treatment and have only limited scope 
for arresting disease progression, let alone restoring structure and function where neurological deficit 
has accumulated. There is a large and unmet clinical need for new treatments in MS, particularly in the 
progressive phase. A key objective in terms of understanding the underlying molecular pathology, is to 
unravel the interrelationship of inflammation and axonal loss in MS; the key therapeutic objective to 
prevent axonal loss and limit demyelination. An intuitive strategy is to promote remyelination to 
achieve axonal protection. Recent advances in human stem cell biology have given rise to 
unprecedented experimental opportunities to study neurodegenerative disease using clinically relevant 
model systems, and patient-derived iPSCs now offer an unparalleled human system for in vitro 
modeling of disease mechanisms and discovering new therapeutic strategies. Proof-of-concept studies 
have already demonstrated the practical feasibility of using both mouse and human in vitro  
iPSC model systems to elucidate both cell-autonomous and non-cell-autonomous mechanisms  
of neurodegeneration [131–133]. At present, the main utility of human stem cell approaches 
therapeutically would appear to be indirect, through the promotion of endogenous repair mechanisms, 
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rather than direct cellular replacement. All existing data converge on the promotion remyelination as 
being the most effective principal therapeutic strategy to slow down, stop and reverse functional 
deficits arising in MS. Human stem cells possess all desirable attributes to help realize this promise, 
both in terms of understanding disease/repair mechanisms but also through promotion of remyelination 
(via different direct and indirect mechanisms). Future research should focus on how to optimally 
harness these attributes to maximally exploit their therapeutic potential for the benefit of MS patients. 
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